학술논문
Increased ERCC1 expression is linked to chromosomal aberrations and adverse tumor biology in prostate cancer
Document Type
article
Author
Frank Jacobsen; Billurvan Taskin; Nathaniel Melling; Charlotte Sauer; Corinna Wittmer; Claudia Hube-Magg; Martina Kluth; Ronald Simon; Dirk Pehrke; Burkhard Beyer; Thomas Steuber; Imke Thederan; Guido Sauter; Thorsten Schlomm; Waldemar Wilczak; Katharina Möller; Sören A. Weidemann; Susanne Burdak-Rothkamm
Source
BMC Cancer, Vol 17, Iss 1, Pp 1-11 (2017)
Subject
Language
English
ISSN
1471-2407
Abstract
Abstract Background Animal model experiments have suggested a role of the DNA repair protein ERCC1 (Excision Repair Cross-Complementation Group 1) in prostate cancer progression. Methods To better understand the impact of ERCC1 protein expression in human prostate cancer, a preexisting tissue microarray (TMA) containing more than 12,000 prostate cancer specimens was analyzed by immunohistochemistry and data were compared with tumor phenotype, PSA recurrence and several of the most common genomic alterations (TMPRSS2:ERG fusions: deletions of PTEN, 6q, 5q, 3p). Results ERCC1 staining was seen in 64.7% of 10,436 interpretable tissues and was considered weak in 37.1%, moderate in 22.6% and strong in 5% of tumors. High-level ERCC1 staining was linked to advanced pT stage, high Gleason grade, positive lymph nodes, high pre-operative serum PSA, and positive surgical margin status (p